首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1468341

2024-2032年按病毒類型（基因工程溶瘤病毒、溶瘤野生型病毒）、應用（實體瘤、黑色素瘤）、最終用途（醫院、專科診所、癌症研究所）和地區分類的溶瘤病毒療法市場報告

Oncolytic Virus Therapies Market Report by Virus Type (Genetically Engineered Oncolytic Viruses, Oncolytic Wild-Type Viruses), Application (Solid Tumors, Melanoma), End Use (Hospitals, Specialty Clinics, Cancer Research Institute), and Region 2024-2032

出版日期: 2024年04月08日 | 出版商:

IMARC | 英文 136 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

IMARC Group年全球溶瘤病毒療法市場規模達1.627億美元。

溶瘤病毒療法是一種利用病毒感染和破壞癌細胞的免疫療法。他們使用各種天然和基因改造病毒，例如單純皰疹病毒、新城疫病毒、痘苗病毒、腺病毒、呼腸孤病毒和小核糖核酸病毒。溶瘤病毒療法會活化危險訊號以產生免疫反應，並廣泛用於治療實體瘤、黑色素瘤和不可切除的病灶。它們還使用僅感染和破壞目標腫瘤細胞的病毒來幫助根除腫瘤。與化療相比，溶瘤病毒療法無毒，療效優越，可延長癌症患者的存活期。因此，它們在醫院、診所和癌症研究機構中得到了廣泛的應用。

溶瘤病毒療法市場趨勢：

全球癌症發生率的上升為市場創造了積極的前景。溶瘤病毒療法因其強大的抗腫瘤特性以及在不傷害周圍組織的情況下準確靶向腫瘤的能力而被廣泛用於治療各種癌症，例如膠質母細胞瘤、乳腺癌、肺癌和前列腺癌。與此一致的是，該療法廣泛用於治療各種類型的黑色素瘤，如血液惡性腫瘤、淋巴瘤、白血病和骨髓瘤，有利於市場成長。此外，患者對手術介入、放射治療、化療和免疫療法等各種癌症治療對健康的負面影響日益擔憂，這極大地推動了市場成長。此外，越來越多的溶瘤病毒（例如皰疹病毒、腺病毒和痘苗病毒）臨床研究數量不斷增加，這些研究正處於最後階段並已證明了出色的實驗結果，正在促進市場成長。其他因素預計將推動市場成長，包括對先進治療和新療法的需求不斷成長，以及多個政府為提高對不同癌症原因的認知並促進早期診斷而採取的更多措施。

本報告回答的關鍵問題

2023年全球溶瘤病毒療法市場規模有多大？
2024-2032年全球溶瘤病毒療法市場的預期成長率是多少？
推動全球溶瘤病毒療法市場的關鍵因素是什麼？
COVID-19 對全球溶瘤病毒療法市場有何影響？
全球溶瘤病毒治療市場的關鍵區域有哪些？
誰是全球溶瘤病毒療法市場的主要參與者/公司？

Oncolytic virus therapies are a form of immunotherapy that utilizes viruses to infect and destroy cancer cells. They use various natural and genetically modified viruses, such as herpes simplex, Newcastle disease, vaccinia, adenovirus, reovirus, and picornavirus. Oncolytic virus therapies activate danger signals for generating an immune response and are widely used for treating solid tumors, melanoma, and unresectable lesions. They also help eradicate tumors using viruses that only infect and destroy targeted tumor cells. As compared to chemotherapy, oncolytic virus therapies are non-toxic, provide superior efficacy, and prolong the survival of cancer patients. As a result, they find extensive applications in hospitals, clinics, and cancer research institutes.

Oncolytic Virus Therapies Market Trends:

The rising incidences of cancer across the globe are creating a positive outlook for the market. Oncolytic virus therapies are widely used to treat various cancers, such as glioblastoma, breast, lung, and prostate cancers, due to their powerful anti-tumor properties and ability to target tumors accurately without harming surrounding tissues. In line with this, the widespread utilization of the therapy to treat various types of melanomas, such as hematological malignancies, lymphoma, leukemia, and myeloma, is favoring the market growth. Furthermore, rising concerns among patients regarding the negative health impact of various cancer treatments, such as surgical intervention, radiotherapy, chemotherapy, and immunotherapy, are providing a considerable boost to the market growth. Additionally, the rising number of clinical studies in oncolytic viruses, such as herpesvirus, adenovirus, and vaccinia virus, that is in the final stages and have demonstrated excellent experimental results are facilitating the market growth. Other factors, including rising demand for advanced treatments and novel therapies and increasing initiatives by several governments to spread awareness regarding different causes of cancer and promote early diagnosis, are anticipated to drive the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global oncolytic virus therapies market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on virus type, application and end use.

Breakup by Virus Type:

Genetically Engineered Oncolytic Viruses

Herpes Simplex Virus

Adenovirus

Vaccinia Virus

Oncolytic Wild-Type Viruses

Reovirus

Newcastle Disease Virus

Vesicular Stomatitis Virus

Breakup by Application:

Solid Tumors

Breast Cancer

Prostate Cancer

Lung Cancer

Glioblastoma

Melanoma

Hematological Malignancies

Lymphoma

Leukemia

Myeloma

Breakup by End Use:

Hospitals

Specialty Clinics

Cancer Research Institute

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., Dnatrix Inc., Genelux Corporation, Lokon Pharma AB, Replimune Group Inc., Rigvir Ltd., Sorrento Therapeutics, Takara Bio Inc. (Takara Holdings Inc.), Targovax, TILT Biotherapeutics Ltd, Transgene SA and Vyriad. Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report

1. What was the size of the global oncolytic virus therapies market in 2023?
2. What is the expected growth rate of the global oncolytic virus therapies market during 2024-2032?
3. What are the key factors driving the global oncolytic virus therapies market?
4. What has been the impact of COVID-19 on the global oncolytic virus therapies market?
5. What are the key regions in the global oncolytic virus therapies market?
6. Who are the key players/companies in the global oncolytic virus therapies market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Oncolytic Virus Therapies Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Virus Type

6.1 Genetically Engineered Oncolytic Viruses
- 6.1.1 Market Trends
- 6.1.2 Key Segments
  - 6.1.2.1 Herpes Simplex Virus
  - 6.1.2.2 Adenovirus
  - 6.1.2.3 Vaccinia Virus
- 6.1.3 Market Forecast
6.2 Oncolytic Wild-Type Viruses
- 6.2.1 Market Trends
- 6.2.2 Key Segments
  - 6.2.2.1 Reovirus
  - 6.2.2.2 Newcastle Disease Virus
  - 6.2.2.3 Vesicular Stomatitis Virus
- 6.2.3 Market Forecast

7 Market Breakup by Application

7.1 Solid Tumors
- 7.1.1 Market Trends
- 7.1.2 Key Segments
  - 7.1.2.1 Breast Cancer
  - 7.1.2.2 Prostate Cancer
  - 7.1.2.3 Lung Cancer
  - 7.1.2.4 Glioblastoma
- 7.1.3 Market Forecast
7.2 Melanoma
- 7.2.1 Market Trends
- 7.2.2 Key Segments
  - 7.2.2.1 Hematological Malignancies
  - 7.2.2.2 Lymphoma
  - 7.2.2.3 Leukemia
  - 7.2.2.4 Myeloma
- 7.2.3 Market Forecast

8 Market Breakup by End Use

8.1 Hospitals
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Specialty Clinics
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Cancer Research Institute
- 8.3.1 Market Trends
- 8.3.2 Market Forecast

9 Market Breakup by Region

9.1 North America
- 9.1.1 United States
  - 9.1.1.1 Market Trends
  - 9.1.1.2 Market Forecast
- 9.1.2 Canada
  - 9.1.2.1 Market Trends
  - 9.1.2.2 Market Forecast
9.2 Asia-Pacific
- 9.2.1 China
  - 9.2.1.1 Market Trends
  - 9.2.1.2 Market Forecast
- 9.2.2 Japan
  - 9.2.2.1 Market Trends
  - 9.2.2.2 Market Forecast
- 9.2.3 India
  - 9.2.3.1 Market Trends
  - 9.2.3.2 Market Forecast
- 9.2.4 South Korea
  - 9.2.4.1 Market Trends
  - 9.2.4.2 Market Forecast
- 9.2.5 Australia
  - 9.2.5.1 Market Trends
  - 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
  - 9.2.6.1 Market Trends
  - 9.2.6.2 Market Forecast
- 9.2.7 Others
  - 9.2.7.1 Market Trends
  - 9.2.7.2 Market Forecast
9.3 Europe
- 9.3.1 Germany
  - 9.3.1.1 Market Trends
  - 9.3.1.2 Market Forecast
- 9.3.2 France
  - 9.3.2.1 Market Trends
  - 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
  - 9.3.3.1 Market Trends
  - 9.3.3.2 Market Forecast
- 9.3.4 Italy
  - 9.3.4.1 Market Trends
  - 9.3.4.2 Market Forecast
- 9.3.5 Spain
  - 9.3.5.1 Market Trends
  - 9.3.5.2 Market Forecast
- 9.3.6 Russia
  - 9.3.6.1 Market Trends
  - 9.3.6.2 Market Forecast
- 9.3.7 Others
  - 9.3.7.1 Market Trends
  - 9.3.7.2 Market Forecast
9.4 Latin America
- 9.4.1 Brazil
  - 9.4.1.1 Market Trends
  - 9.4.1.2 Market Forecast
- 9.4.2 Mexico
  - 9.4.2.1 Market Trends
  - 9.4.2.2 Market Forecast
- 9.4.3 Others
  - 9.4.3.1 Market Trends
  - 9.4.3.2 Market Forecast
9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast

10 SWOT Analysis

10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
- 14.3.1 Amgen Inc.
  - 14.3.1.1 Company Overview
  - 14.3.1.2 Product Portfolio
  - 14.3.1.3 Financials
  - 14.3.1.4 SWOT Analysis
- 14.3.2 Dnatrix Inc.
  - 14.3.2.1 Company Overview
  - 14.3.2.2 Product Portfolio
- 14.3.3 Genelux Corporation
  - 14.3.3.1 Company Overview
  - 14.3.3.2 Product Portfolio
- 14.3.4 Lokon Pharma AB
  - 14.3.4.1 Company Overview
  - 14.3.4.2 Product Portfolio
- 14.3.5 Replimune Group Inc.
  - 14.3.5.1 Company Overview
  - 14.3.5.2 Product Portfolio
- 14.3.6 Rigvir Ltd.
  - 14.3.6.1 Company Overview
  - 14.3.6.2 Product Portfolio
- 14.3.7 Sorrento Therapeutics
  - 14.3.7.1 Company Overview
  - 14.3.7.2 Product Portfolio
  - 14.3.7.3 Financials
- 14.3.8 Takara Bio Inc. (Takara Holdings Inc.)
  - 14.3.8.1 Company Overview
  - 14.3.8.2 Product Portfolio
  - 14.3.8.3 Financials
- 14.3.9 Targovax
  - 14.3.9.1 Company Overview
  - 14.3.9.2 Product Portfolio
- 14.3.10 TILT Biotherapeutics Ltd
  - 14.3.10.1 Company Overview
  - 14.3.10.2 Product Portfolio
- 14.3.11 Transgene SA
  - 14.3.11.1 Company Overview
  - 14.3.11.2 Product Portfolio
  - 14.3.11.3 Financials
- 14.3.12 Vyriad
  - 14.3.12.1 Company Overview
  - 14.3.12.2 Product Portfolio

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.

簡介目錄圖表

List of Figures

Figure 1: Global: Oncolytic Virus Therapies Market: Major Drivers and Challenges
Figure 2: Global: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018-2023
Figure 3: Global: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 4: Global: Oncolytic Virus Therapies Market: Breakup by Virus Type (in %), 2023
Figure 5: Global: Oncolytic Virus Therapies Market: Breakup by Application (in %), 2023
Figure 6: Global: Oncolytic Virus Therapies Market: Breakup by End Use (in %), 2023
Figure 7: Global: Oncolytic Virus Therapies Market: Breakup by Region (in %), 2023
Figure 8: Global: Oncolytic Virus Therapies (Genetically Engineered Oncolytic Viruses) Market: Sales Value (in Million US$), 2018 & 2023
Figure 9: Global: Oncolytic Virus Therapies (Genetically Engineered Oncolytic Viruses) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 10: Global: Oncolytic Virus Therapies (Oncolytic Wild-Type Viruses) Market: Sales Value (in Million US$), 2018 & 2023
Figure 11: Global: Oncolytic Virus Therapies (Oncolytic Wild-Type Viruses) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 12: Global: Oncolytic Virus Therapies (Solid Tumors) Market: Sales Value (in Million US$), 2018 & 2023
Figure 13: Global: Oncolytic Virus Therapies (Solid Tumors) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 14: Global: Oncolytic Virus Therapies (Melanoma) Market: Sales Value (in Million US$), 2018 & 2023
Figure 15: Global: Oncolytic Virus Therapies (Melanoma) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 16: Global: Oncolytic Virus Therapies (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
Figure 17: Global: Oncolytic Virus Therapies (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 18: Global: Oncolytic Virus Therapies (Specialty Clinics) Market: Sales Value (in Million US$), 2018 & 2023
Figure 19: Global: Oncolytic Virus Therapies (Specialty Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 20: Global: Oncolytic Virus Therapies (Cancer Research Institute) Market: Sales Value (in Million US$), 2018 & 2023
Figure 21: Global: Oncolytic Virus Therapies (Cancer Research Institute) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 22: North America: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 23: North America: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 24: United States: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 25: United States: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 26: Canada: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 27: Canada: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 28: Asia-Pacific: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 29: Asia-Pacific: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 30: China: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 31: China: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 32: Japan: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 33: Japan: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 34: India: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 35: India: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 36: South Korea: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 37: South Korea: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 38: Australia: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 39: Australia: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 40: Indonesia: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 41: Indonesia: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 42: Others: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 43: Others: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 44: Europe: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 45: Europe: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 46: Germany: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 47: Germany: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 48: France: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 49: France: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 50: United Kingdom: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 51: United Kingdom: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 52: Italy: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 53: Italy: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 54: Spain: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 55: Spain: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 56: Russia: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 57: Russia: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 58: Others: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 59: Others: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 60: Latin America: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 61: Latin America: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 62: Brazil: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 63: Brazil: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 64: Mexico: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 65: Mexico: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 66: Others: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 67: Others: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 68: Middle East and Africa: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
Figure 69: Middle East and Africa: Oncolytic Virus Therapies Market: Breakup by Country (in %), 2023
Figure 70: Middle East and Africa: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 71: Global: Oncolytic Virus Therapies Industry: SWOT Analysis
Figure 72: Global: Oncolytic Virus Therapies Industry: Value Chain Analysis
Figure 73: Global: Oncolytic Virus Therapies Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Oncolytic Virus Therapies Market: Key Industry Highlights, 2023 & 2032
Table 2: Global: Oncolytic Virus Therapies Market Forecast: Breakup by Virus Type (in Million US$), 2024-2032
Table 3: Global: Oncolytic Virus Therapies Market Forecast: Breakup by Application (in Million US$), 2024-2032
Table 4: Global: Oncolytic Virus Therapies Market Forecast: Breakup by End Use (in Million US$), 2024-2032
Table 5: Global: Oncolytic Virus Therapies Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 6: Global: Oncolytic Virus Therapies Market: Competitive Structure
Table 7: Global: Oncolytic Virus Therapies Market: Key Players

02-2729-4219

+886-2-2729-4219